Resumption of oral anticoagulants after intracerebral hemorrhage does not increase the risk of recurrent hemorrhage and reduces the risk of thromboembolism and all-cause mortality.
Does resumption of oral anticoagulants reduce thromboembolism and mortality without increasing recurrent intracerebral hemorrhage in patients after an intracerebral hemorrhage?
Resuming oral anticoagulation after intracerebral hemorrhage appears to reduce thromboembolism and mortality without increasing recurrent bleeding, though optimal timing remains unclear and requires individualized assessment.
PURPOSE OF REVIEW: Decision-making on resuming oral anticoagulant (OAC) after intracerebral hemorrhage (ICH) evokes significant debate among clinicians. Such patients have been excluded from randomized clinical trials. This review article provides a comprehensive summary of the evidence on anticoagulation resumption after ICH. RECENT FINDINGS: OAC resumption does not increase the risk of recurrent ICH and can also reduce the risk of all-cause mortality. OAC cessation exposes patients to a significantly higher risk of thromboembolism, which could be reduced by resumption. The optimal timing of anticoagulation resumption after ICH is still unknown. Both early ( 4 weeks) resumption should be reached only after very careful assessment of risks for ICH recurrence and thromboembolism. The introduction of new oral anticoagulants and other interventions, such as left atrial appendage closure, has provided some patients with more alternatives. Given the lack of high-quality evidence to guide clinical decision-making, clinicians must carefully balance the risks of thromboembolism and recurrent ICH in individual patients. We propose a management approach which would facilitate the decision-making process on whether anticoagulation is appropriate, as well as when and how to restart anticoagulation after ICH.
Li et al. (Sun,) conducted a review in Intracerebral hemorrhage. Oral anticoagulant resumption vs. No oral anticoagulant resumption was evaluated. Resumption of oral anticoagulants after intracerebral hemorrhage does not increase the risk of recurrent hemorrhage and reduces the risk of thromboembolism and all-cause mortality.